Ranitidine and Envarsus xr drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ranitidine (ranitidine) and Envarsus xr (tacrolimus). Common drug interactions include liver transplant rejection among females and hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Ranitidine and Envarsus xr. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

What is Envarsus xr?

Envarsus xr has active ingredients of tacrolimus. eHealthMe is studying from 3,819 Envarsus xr users. Check the latest studies of Envarsus xr.



On Jul, 09, 2026

22 people who take Ranitidine and Envarsus xr together, and have interactions are studied.

Ranitidine and Envarsus xr drug interactions.

What are the common drug interactions of Ranitidine and Envarsus Xr, by gender? *:

female:

  1. Liver transplant rejection (failure of liver transplant)
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Anxiety
  4. Bacteraemia (presence of bacteria in the blood)
  5. Blood creatinine increased
  6. Death
  7. Depression
  8. Drug level decreased
  9. Emotional distress
  10. Pain

male:

  1. Hypertension (high blood pressure)
  2. Anaemia (lack of blood)
  3. Renal failure (kidney dysfunction)
  4. Social problem
  5. Dry mouth
  6. Hospitalisation
  7. Tremor (trembling or shaking movements in one or more parts of your body)
  8. Blood creatine increased
  9. Cryoglobulinaemia (blood contains large amounts of cryoglobulins - proteins)
  10. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)

What are the common drug interactions of Ranitidine and Envarsus Xr, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Blood creatinine increased
  2. Drug level decreased

10-19:

n/a

20-29:

  1. Liver transplant rejection (failure of liver transplant)
  2. Bacteraemia (presence of bacteria in the blood)

30-39:

  1. Anaemia (lack of blood)
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Anxiety
  4. Emotional distress
  5. Gait disturbance
  6. Hyperkalaemia (damage to or disease of the kidney)
  7. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  8. Hypertension (high blood pressure)
  9. Pain
  10. Partner stress

40-49:

  1. Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
  2. Pancreatitis (inflammation of pancreas)
  3. Transplant rejection (a transplant material is not worked)

50-59:

  1. Abdominal pain
  2. Blood creatine increased
  3. Cough
  4. Diarrhoea
  5. Influenza
  6. Pancreatitis (inflammation of pancreas)

60+:

  1. Skin cancer
  2. Cryoglobulinaemia (blood contains large amounts of cryoglobulins - proteins)
  3. Lymphadenopathy (disease or enlargement of lymph nodes)
  4. Nephritic syndrome (a collection of signs (known as a syndrome) associated with disorders affecting the kidneys, more specifically glomerular disorders)
  5. Nephrotic syndrome (kidney disease with proteinuria, hypoalbuminemia, and oedema)
  6. Oliguria (not enough urine)
  7. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
  8. Squamous cell carcinoma (a cancer of a kind of epithelial cell)
  9. Type 2 diabetes mellitus
  10. Uveitis (inflammation of the uvea)

What are the existing conditions these people have? *

  1. High Blood Pressure: 6 people, 27.27%
  2. Diabetes: 5 people, 22.73%
  3. Pain: 2 people, 9.09%
  4. Hypersensitivity: 2 people, 9.09%
  5. Hiv Infection: 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Ranitidine and Envarsus xr?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ranitidine and Envarsus xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Envarsus xr:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ranitidine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Envarsus xr and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine and tacrolimus (the active ingredients of Ranitidine and Envarsus xr, respectively), and Ranitidine and Envarsus xr (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: